Oxford BioMedica PLC
LSE:OXB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
166.8
445
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Oxford BioMedica PLC
Oxford BioMedica PLC
Cash & Cash Equivalents
Oxford BioMedica PLC
Cash & Cash Equivalents Peer Comparison
CNTA
AUTL
BCYC
IMCR
GNS
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Cash & Cash Equivalents
£81.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
26%
|
CAGR 10-Years
18%
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Cash & Cash Equivalents
$128m
|
CAGR 3-Years
161%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Cash & Cash Equivalents
$239.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Cash & Cash Equivalents
$890.9m
|
CAGR 3-Years
51%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Cash & Cash Equivalents
£442.6m
|
CAGR 3-Years
51%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Cash & Cash Equivalents
£42.5m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
6%
|
See Also
What is Oxford BioMedica PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
81.4m
GBP
Based on the financial report for Jun 30, 2024, Oxford BioMedica PLC's Cash & Cash Equivalents amounts to 81.4m GBP.
What is Oxford BioMedica PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
18%
Over the last year, the Cash & Cash Equivalents growth was -37%. The average annual Cash & Cash Equivalents growth rates for Oxford BioMedica PLC have been 10% over the past three years , 26% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
